| Intervention period | Post-ingestion period | |||||
---|---|---|---|---|---|---|---|
Item | Group | n | Week-0 | Week-4 | Week-8 | Week-12 | Week-16 |
Energy (kcal/3d) | Placebo | 14 | 6075 ± 1336 | 5925 ± 934 | 5648 ± 1108** | 5623 ± 872 | 5488 ± 924* |
GH | 15 | 5599 ± 1387 | 5748 ± 1500 | 5383 ± 1250 | 5322 ± 1259 | 5328 ± 1013 | |
GH + Caf 25 | 15 | 5606 ± 1270 | 5512 ± 1031 | 5252 ± 1340 | 4981 ± 1291 | 5155 ± 1395 | |
GH + Caf 50 | 15 | 5240 ± 1463 | 5774 ± 1666 | 5425 ± 1538 | 5302 ± 1723 | 5272 ± 1635 | |
GH + Caf 75 | 15 | 5727 ± 929 | 5268 ± 1369 | 5546 ± 1302 | 5119 ± 1538 | 5401 ± 1618 | |
Exercise volume (step/3d) | Placebo | 14 | 21661 ± 12162 | 22372 ± 9366 | 27058 ± 11735 | 25258 ± 10247 | 23994 ± 10039 |
GH | 15 | 17118 ± 7809 | 22161 ± 15033 | 19231 ± 8677 | 22738 ± 11305* | 20298 ± 8622 | |
GH + Caf 25 | 15 | 19929 ± 8679 | 22946 ± 14412 | 22350 ± 16172 | 19656 ± 16855 | 22996 ± 14817 | |
GH + Caf 50 | 15 | 23513 ± 13156 | 21881 ± 12157 | 22491 ± 9911 | 23005 ± 12524 | 24650 ± 12288 | |
GH + Caf 75 | 15 | 18843 ± 7455 | 19828 ± 6532 | 24016 ± 8703 | 24036 ± 9488 | 23972 ± 8216 |